查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081505

腦生物標記市場：2026-2032年全球市場預測（按生物標記類型、檢體類型、技術、臨床適應症、應用和最終用戶分類）

Brain Biomarkers Market by Biomarker Type, Sample Type, Technology, Clinical Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腦生物標記市場將成長至 395.5 億美元，複合年成長率為 18.07%。

主要市場統計數據
基準年 2025 123.6億美元
預計年份：2026年 144.3億美元
預測年份 2032 395.5億美元
複合年成長率 (%) 18.07%

診斷服務提供者的《執行摘要

腦生物標記的作用正從專門的研究工具擴展到神經退化性疾病診斷、創傷性腦損傷評估、精神病學研究和治療監測等常規臨床決策。該領域涵蓋腦脊髓液生物標記、血液生物標記、神經影像生物標記、電生理學、基因組學、蛋白質組學、代謝體學，甚至包括透過穿戴式和連網型設備獲取的數位生物標記。

腦生物標記趨勢的變革性變化

腦生物標記的發展趨勢正朝著早期檢測、微創檢體採集以及利用生物標記進行患者分層的方向轉變。 FDA分別於2023年和2024年批准了lecanemab和donanemab等抗澱粉樣蛋白療法，這增加了在製定治療策略前確認澱粉樣蛋白和Tau沉積的需求，從而導致對PET成像、腦脊髓液分析和檢驗的血液檢測的需求增加。

人工智慧對大腦生物標記的累積影響

人工智慧 (AI) 透過改進影像量化、模式識別和多模態風險建模，正在加速對腦生物標記的解讀。根據美國食品藥物管理局 (FDA) 的公開清單，獲準的搭載人工智慧和機器學習技術的醫療設備正在迅速成長，其中醫學影像領域佔據最大佔有率，神經系統應用也在不斷擴展。

關於腦生物標記的關鍵區域性見解

北美在臨床應用方面處於主導地位。這是因為美國擁有先進的神經病學網路、經FDA已通過核准的診斷路徑、美國國立衛生研究院（NIH）資助的研究、大規模的阿茲海默症群體，以及與實證醫學相關的保險體系。在加拿大，公共研究機構、記憶診所和省級醫療保健系統為應用提供支持，但報銷途徑、檢測機會和先進影像技術的獲取途徑因地區而異。

領先的團隊對腦生物標記的見解

七國集團（G7）在腦生物標記創新領域持續發揮核心作用。這是因為美國、加拿大、日本、德國、法國、義大利和英國擁有世界領先的製藥公司、失智症隊列研究、診斷研發公司、大學醫學中心以及影響全球醫療設備標準的監管體系。歐盟在體外診斷法規框架下協調證據生成以及支持檢驗、真實世界證據、數據互通性和臨床指南制定的跨境研究計畫中發揮著至關重要的作用。

各國對腦生物標記的深入見解

美國是最具影響力的市場，因為FDA的決策、CMS的保險覆蓋政策、美國國立衛生研究院（NIH）的津貼、退伍軍人事務部（VHA）的研究以及大規模的阿茲海默症隊列正在塑造基於生物標記的診斷確認和治療監測的全球標準。加拿大則強調透過大學醫院和省級醫療保健系統以研究主導應用。同時，墨西哥和巴西代表著拉丁美洲快速成長的市場，這得益於人們對失智症認知的提高、私人診斷實驗室的擴張以及對神經科醫生主導的檢測需求的不斷成長。

為腦生物標記行業的領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗的檢測方法、標準化的檢體處理流程以及清晰的解讀框架，以幫助神經科醫生根據檢測結果採取相應措施。實驗室需要針對阿茲海默症、帕金森氏症候群、多發性硬化症、創傷性腦損傷、神經發炎和治療監測等高影響力應用場景，調整其腦生物標記檢測計畫。

腦生物標記分析的調查方法

本執行摘要基於公共衛生機構、監管資料庫、同行評審的神經病學文獻、最新臨床指南以及公開的機構資訊披露的二手研究。資訊來源包括世界衛生組織（WHO）、美國食品藥物管理局（CMS）、美國國立衛生研究院（NIH）、阿茲海默症協會以及國際領先的神經病學期刊。

關於腦生物標記商業機會的結論

隨著生物學證據在治療方案選擇、診斷和監測中變得日益重要，腦生物標記在精準神經病學中也變得不可或缺。最大的商業性和臨床機會在於診斷準確性、與臨床工作流程的整合、保險報銷的合理性以及可擴展的檢查室運作等方面的整合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 腦生物標記市場：依生物標記類型分類

  • 影像生物標記
    • MRI生物標記
    • 核醫學影像生物標記
    • 基於CT的生物標記
  • 分子生物標記
    • 基因生物標記
    • 蛋白質體學生物標記
    • 代謝體學物標誌物
    • 脂質組體學物標誌物
    • 轉錄組生物標記
  • 電生理生物標記
    • 腦電圖生物標記物
    • 磁腦電圖（EMG）生物標記物
    • 誘發電位生物標記物
  • 數位生物標記
    • 穿戴式裝置衍生的生物標記
    • 基於智慧型手機的生物標記
    • 數位表現型生物標記

第8章：腦生物標記市場：依樣本類型分類

  • 血
    • 電漿
    • 血清
  • 腦脊髓液
  • 唾液
  • 尿
  • 腦組織

第9章：腦生物標記市場：依技術分類

  • 磁振造影
  • 正子斷層掃描
  • 電腦斷層掃描
  • 次世代定序
  • 腦電圖（EEG）
  • 質譜分析
  • 微陣列

第10章：腦生物標記市場：依適應症分類

  • 神經退化性疾病
  • 精神疾病
  • 神經發育障礙
  • 創傷性腦損傷
  • 中風和腦血管疾病
  • 腦腫瘤
  • 神經發炎與去髓鞘化疾病
  • 中樞神經系統感染疾病
  • 癲癇和癲癇發作

第11章 腦生物標記市場：依應用領域分類

  • 篩檢和風險評估
  • 診斷
  • 前景
  • 治療反應監測
  • 藥物發現與臨床研究

第12章 腦生物標記市場：依最終用戶分類

  • 受託研究機構
  • 診斷檢查室和診斷影像中心
  • 醫院
  • 製藥和生物技術公司
  • 學術研究機構
  • 神經內科和精神科專科診所
  • 政府和公共衛生機構

第13章 腦生物標記市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 腦生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Revvity, Inc.
  • GE HealthCare Technologies Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • DiaSorin SpA
  • Danaher Corporation
  • QIAGEN NV
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Fujirebio Inc.
  • Biogen, Inc.
  • Altoida
  • ANT Neuro
  • BioSensics, LLC
  • BrainScope Company Inc
  • Bruker Corporation
  • C2N Diagnostics
  • Cortechs.ai
  • EMOTIV
  • g.tec medical engineering GmbH
  • Hologic, Inc.
  • IXICO plc
  • Lantheus Holdings, Inc.
  • Linus Health
  • Myriad Genetics, Inc.
  • Neurotrack Technologies, Inc.
  • Quanterix Corporation
  • Quibim, SL
  • RUNE LABS, INC.
  • Synaptive Medical Inc.
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market is projected to grow by USD 39.55 billion at a CAGR of 18.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.36 billion
Estimated Year [2026] USD 14.43 billion
Forecast Year [2032] USD 39.55 billion
CAGR (%) 18.07%

Brain Biomarkers Executive Summary for Diagnostic Providers

Brain biomarkers are moving from specialist research tools into routine clinical decision-making for neurodegenerative disease diagnostics, traumatic brain injury assessment, psychiatric research, and therapy monitoring. The field spans cerebrospinal fluid biomarkers, blood-based biomarkers, neuroimaging biomarkers, electrophysiology, genomics, proteomics, metabolomics, and digital biomarkers captured through wearables and connected devices.

The World Health Organization reports more than 55 million people living with dementia worldwide and nearly 10 million new cases each year, while neurological conditions affect more than 3 billion people globally. For diagnostic providers, this creates a clear opportunity to build validated, scalable, and clinically interpretable brain biomarker workflows that support earlier detection, differential diagnosis, patient stratification, and longitudinal disease monitoring.

Transformative Shifts in the Brain Biomarkers Landscape

The brain biomarkers landscape is shifting toward earlier detection, less invasive sampling, and biomarker-confirmed patient stratification. FDA approvals of anti-amyloid therapies such as lecanemab in 2023 and donanemab in 2024 have increased the need for amyloid and tau confirmation before treatment decisions, strengthening demand for PET imaging, CSF testing, and validated blood-based assays.

Clinical adoption is also changing as neurology moves from symptom-led diagnosis to biology-led assessment. The 2024 Alzheimer's Association criteria emphasize biomarker evidence, while hospitals and reference laboratories are investing in standardized pre-analytics, longitudinal monitoring, and integrated reports that combine biomarker results with cognitive, imaging, genetic, and clinical context. This shift is also raising expectations for quality control, cut-off harmonization, clinician education, and equitable access to advanced neurological diagnostics.

Cumulative Impact of Artificial Intelligence on Brain Biomarkers

Artificial intelligence is accelerating brain biomarker interpretation by improving image quantification, pattern recognition, and multimodal risk modeling. FDA public listings show rapid growth in authorized AI and machine learning-enabled medical devices, with medical imaging representing the largest category and neurology-related applications expanding.

For diagnostic providers, AI can reduce reader variability in MRI and PET analysis, support automated segmentation of brain structures, and integrate blood, CSF, genetic, electrophysiology, and digital data into clinically useful probability scores. However, adoption must be anchored in transparent validation, demographic bias assessment, cybersecurity controls, data provenance, explainability, and clinician oversight to meet laboratory, hospital, payer, and regulator expectations.

Key Regional Insights for Brain Biomarkers

North America leads clinical implementation because the United States combines advanced neurology networks, FDA-cleared diagnostic pathways, National Institutes of Health-backed research, large Alzheimer's disease cohorts, and payer frameworks tied to evidence generation. Canada supports adoption through public research institutions, memory clinics, and provincial health systems, although reimbursement pathways, test availability, and access to advanced imaging vary by jurisdiction.

Europe benefits from coordinated dementia strategies, strong academic consortia, and European Union regulation that is raising evidence expectations for in vitro diagnostics. The region is strengthening standardization for CSF, blood-based, and imaging biomarkers, while differences in national reimbursement and laboratory infrastructure continue to shape adoption. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in aging-related healthcare capacity, hospital-based neurology, imaging infrastructure, precision medicine, and digital health, supported by rapidly growing demand linked to population aging and neurological disease burden. Latin America is advancing through private diagnostic networks, academic neurology centers, and rising dementia awareness, with Brazil and Mexico serving as important access hubs. The Middle East is increasing investment in specialty care, genomics, advanced imaging, and medical tourism, particularly through high-income health systems. Africa shows growing clinical need for brain biomarker-enabled diagnosis, but adoption is constrained by specialist shortages, affordability, laboratory capacity, and limited access to PET tracers, advanced MRI, and standardized biomarker testing.

Key Group Insights for Brain Biomarkers

The G7 remains central to brain biomarker innovation because the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom host leading pharmaceutical sponsors, dementia cohorts, diagnostic developers, academic medical centers, and regulatory systems that influence global evidence standards. The European Union is important for harmonized evidence generation under the In Vitro Diagnostic Regulation and for cross-border research programs that support assay validation, real-world evidence, data interoperability, and clinical guideline development.

BRICS countries are increasingly relevant as China, India, Brazil, Russia, and South Africa expand neurology care, hospital infrastructure, medical research participation, and clinical trial activity, although access remains uneven across urban and rural populations. ASEAN markets are improving diagnostic access through urban hospital systems, expanding private healthcare, and growing digital health adoption, while the GCC is investing in specialty care, genomics, advanced imaging, and medical tourism to support precision neurology. NATO markets overlap with many high-income health systems where secure health data infrastructure, defense-linked traumatic brain injury research, and advanced rehabilitation programs support biomarker development and implementation.

Key Country Insights for Brain Biomarkers

The United States is the most influential country market because FDA decisions, CMS coverage policies, National Institutes of Health funding, Veterans Health Administration research, and large Alzheimer's disease cohorts shape global standards for biomarker-confirmed diagnosis and therapy monitoring. Canada emphasizes research-driven adoption through academic hospitals and provincial systems, while Mexico and Brazil represent growing Latin American access markets with rising dementia awareness, expanding private diagnostics, and increasing demand for neurologist-supported testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong neurology centers with increasing demand for biomarker-confirmed diagnosis, especially in Alzheimer's disease, Parkinsonian syndromes, multiple sclerosis, and rare neurological conditions. Germany and France benefit from advanced hospital infrastructure and specialist networks, the United Kingdom supports implementation through research-led memory services and health technology evaluation, and Italy and Spain show growing use of imaging and laboratory-based neurological diagnostics. Russia remains shaped by uneven access, local regulatory dynamics, and regional differences in specialist availability.

Across Asia-Pacific, China is scaling neuroscience research, hospital capacity, and precision medicine programs; India offers high-volume unmet need driven by population scale and expanding private healthcare; Japan has strong aging-related demand and established neurological care pathways; South Korea supports technology-led diagnostics, digital health, and hospital-based innovation; and Australia combines clinical research strength with organized specialist networks and public health attention to dementia and brain health.

Actionable Recommendations for Brain Biomarker Leaders

Industry leaders should prioritize clinically validated assays, standardized sample handling, and clear interpretation frameworks that help neurologists act on results. Laboratories should align brain biomarker menus with high-impact use cases such as Alzheimer's disease, Parkinsonian syndromes, multiple sclerosis, traumatic brain injury, neuroinflammation, and therapy monitoring.

Vendors should build partnerships with academic memory clinics, imaging centers, AI developers, biobanks, and pharmaceutical sponsors. The strongest commercial strategies will combine analytical validity, clinical validity, health-economic evidence, payer engagement, diverse cohort validation, privacy-by-design data governance, and interoperable reporting that fits electronic health record workflows. Leaders should also invest in clinician education, reflex testing protocols, external quality assessment, and real-world evidence programs to support adoption across hospitals, reference laboratories, and specialty neurology practices.

Research Methodology for Brain Biomarker Analysis

This executive summary is grounded in secondary research from public health agencies, regulatory databases, peer-reviewed neurology literature, clinical guideline updates, and publicly available institutional disclosures. Sources considered include the World Health Organization, U.S. FDA, CMS, NIH, Alzheimer's Association, and major international neurology publications.

The methodology emphasizes verified disease-burden data, regulatory milestones, technology adoption evidence, clinical guideline direction, and regional healthcare infrastructure indicators. Insights were synthesized to support executive decision-making while avoiding unsupported market-size claims, promotional language, company references, or unverified performance comparisons. Regional and country narratives were developed by triangulating public health burden, regulatory readiness, specialty care capacity, imaging and laboratory access, and the maturity of precision neurology infrastructure.

Conclusion on the Brain Biomarkers Opportunity

Brain biomarkers are becoming essential to precision neurology as treatment selection, diagnosis, and monitoring increasingly require biological confirmation. The commercial and clinical opportunity is strongest where diagnostic accuracy, clinical workflow integration, reimbursement evidence, and scalable laboratory operations converge.

Diagnostic providers that invest now in validated blood, CSF, imaging, electrophysiology, genetic, and digital biomarker capabilities can strengthen their role in the next generation of neurological care. Success will depend on quality systems, standardized pre-analytics, AI governance, secure data integration, clinician trust, and evidence that demonstrates better decision-making for patients and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Brain Biomarkers Market, by Biomarker Type

  • 7.1. Imaging Biomarkers
    • 7.1.1. MRI Biomarkers
    • 7.1.2. Nuclear Imaging Biomarkers
    • 7.1.3. CT-Based Biomarkers
  • 7.2. Molecular Biomarkers
    • 7.2.1. Genomic Biomarkers
    • 7.2.2. Proteomic Biomarkers
    • 7.2.3. Metabolomic Biomarkers
    • 7.2.4. Lipidomic Biomarkers
    • 7.2.5. Transcriptomic Biomarkers
  • 7.3. Electrophysiological Biomarkers
    • 7.3.1. Electroencephalography Biomarkers
    • 7.3.2. Magnetoencephalography Biomarkers
    • 7.3.3. Evoked Potential Biomarkers
  • 7.4. Digital Biomarkers
    • 7.4.1. Wearable-Derived Biomarkers
    • 7.4.2. Smartphone-Based Biomarkers
    • 7.4.3. Digital Phenotyping Biomarkers

8. Brain Biomarkers Market, by Sample Type

  • 8.1. Blood
    • 8.1.1. Plasma
    • 8.1.2. Serum
  • 8.2. Cerebrospinal Fluid
  • 8.3. Saliva
  • 8.4. Urine
  • 8.5. Brain Tissue

9. Brain Biomarkers Market, by Technology

  • 9.1. Magnetic Resonance Imaging
  • 9.2. Positron Emission Tomography
  • 9.3. Computed Tomography
  • 9.4. Next-Generation Sequencing
  • 9.5. Electroencephalography
  • 9.6. Mass Spectrometry
  • 9.7. Microarray

10. Brain Biomarkers Market, by Clinical Indication

  • 10.1. Neurodegenerative Disorders
  • 10.2. Psychiatric Disorders
  • 10.3. Neurodevelopmental Disorders
  • 10.4. Traumatic Brain Injury
  • 10.5. Stroke & Cerebrovascular Disorders
  • 10.6. Brain Tumors
  • 10.7. Neuroinflammatory & Demyelinating Disorders
  • 10.8. Central Nervous System Infections
  • 10.9. Epilepsy & Seizure Disorders

11. Brain Biomarkers Market, by Application

  • 11.1. Screening & Risk Assessment
  • 11.2. Diagnosis
  • 11.3. Prognosis
  • 11.4. Treatment Response Monitoring
  • 11.5. Drug Discovery & Clinical Research

12. Brain Biomarkers Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Diagnostic Laboratories & Imaging Centers
  • 12.3. Hospitals
  • 12.4. Pharmaceutical & Biotechnology Companies
  • 12.5. Academic & Research Institutes
  • 12.6. Specialty Neurology & Psychiatry Clinics
  • 12.7. Government & Public Health Institutions

13. Brain Biomarkers Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Brain Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. F. Hoffmann-La Roche Ltd
  • 17.3. Thermo Fisher Scientific Inc.
  • 17.4. Siemens Healthineers AG
  • 17.5. Revvity, Inc.
  • 17.6. GE HealthCare Technologies Inc.
  • 17.7. Illumina, Inc.
  • 17.8. Koninklijke Philips N.V.
  • 17.9. Merck KGaA
  • 17.10. DiaSorin S.p.A.
  • 17.11. Danaher Corporation
  • 17.12. QIAGEN N.V.
  • 17.13. Bio-Rad Laboratories, Inc.
  • 17.14. Bio-Techne Corporation
  • 17.15. Fujirebio Inc.
  • 17.16. Biogen, Inc.
  • 17.17. Altoida
  • 17.18. ANT Neuro
  • 17.19. BioSensics, LLC
  • 17.20. BrainScope Company Inc
  • 17.21. Bruker Corporation
  • 17.22. C2N Diagnostics
  • 17.23. Cortechs.ai
  • 17.24. EMOTIV
  • 17.25. g.tec medical engineering GmbH
  • 17.26. Hologic, Inc.
  • 17.27. IXICO plc
  • 17.28. Lantheus Holdings, Inc.
  • 17.29. Linus Health
  • 17.30. Myriad Genetics, Inc.
  • 17.31. Neurotrack Technologies, Inc.
  • 17.32. Quanterix Corporation
  • 17.33. Quibim, S.L.
  • 17.34. RUNE LABS, INC.
  • 17.35. Synaptive Medical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BRAIN BIOMARKERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRI BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRI BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 259. GCC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 261. GCC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. GCC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. GCC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 297. G7 BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. G7 BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. NATO BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 309. NATO BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. NATO BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. NATO BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. NATO BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. MEXICO BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 354. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 358. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 359. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2018-2032 (USD MILLION)
  • TABLE 360. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 361. BRAZIL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 362. U